Wall Street Journal
http://online.wsj.com/home-page

Novavax Develops Vaccine Candidate for Recently Identified Coronavirus
By Saabira Chaudhuri
Excerpt
June 6, 2013, 7:32 a.m. ET
Novavax Inc. (NVAX) said it has successfully produced a vaccine candidate designed to provide protection against the recently emerging Middle East Respiratory Syndrome Coronavirus…

…The vaccine candidate, which was made using Novavax’ recombinant nanoparticle vaccine technology, is based on the major surface spike protein.

Also called MERS-CoV, Middle East Respiratory Syndrome Coronavirus was first identified in September by an Egyptian virologist, who isolated the previously unknown coronavirus from the lungs of a 60-year-old patient with pneumonia and renal failure…

…Novavax had previously produced a recombinant nanoparticle vaccine candidate for the SARS-CoV virus which was similarly based on its major surface S protein.

Novavax’ SARS-CoV vaccine candidate study demonstrated immunogenicity and complete protection of animals in a live viral challenge.
http://online.wsj.com/article/BT-CO-20130606-703919.html